Can metformin be used in patients with Chronic Kidney Disease (CKD)?

Metformin Use in Chronic Kidney Disease

Metformin can be safely used in patients with CKD who have an eGFR ≥30 ml/min per 1.73 m², with appropriate dose adjustments based on kidney function. 1, 2, 3

Recommendations Based on eGFR

eGFR ≥60 ml/min per 1.73 m²

• Continue standard metformin dosing without adjustment 1
• Monitor kidney function at least annually 1

eGFR 45-59 ml/min per 1.73 m²

• Continue metformin at current dose 1, 3, 4
• Consider dose reduction in patients with additional risk factors for lactic acidosis (advanced age, liver disease) 3, 4
• Increase monitoring of kidney function to every 3-6 months 1

eGFR 30-44 ml/min per 1.73 m²

• Reduce metformin dose to half the maximum recommended dose (typically 1000 mg daily) 1, 3, 1
• Monitor kidney function every 3-6 months 1
• Monitor for vitamin B12 deficiency, especially if treatment duration exceeds 4 years 1

eGFR <30 ml/min per 1.73 m²

• Discontinue metformin 1, 2, 3
• Do not initiate metformin 1, 5
• Consider alternative glucose-lowering medications appropriate for advanced CKD 2, 1

Risk of Lactic Acidosis

• The risk of metformin-associated lactic acidosis is rare, with an estimated upper limit of 8-10 cases per 100,000 patient-years 6, 7
• Risk increases with declining kidney function, particularly when eGFR falls below 30 ml/min/1.73 m² 5, 8
• Most cases of lactic acidosis occur in the setting of acute illness or conditions causing hypoperfusion and hypoxemia 5, 3
• Temporary discontinuation of metformin is recommended during:
  • Acute kidney injury 5
  • Iodinated contrast imaging procedures (for patients with eGFR 30-60 ml/min/1.73 m²) 5
  • Surgery or procedures requiring restricted food and fluid intake 5
  • Acute conditions that may cause tissue hypoxia (heart failure, sepsis, shock) 5

Special Considerations

• Kidney transplant recipients with T2D and eGFR ≥30 ml/min/1.73 m² can be treated with metformin following the same recommendations as other CKD patients 1, 2
• Avoid excessive alcohol intake in patients taking metformin, as alcohol potentiates metformin's effect on lactate metabolism 5
• Metformin should be used cautiously in patients with hepatic impairment due to impaired lactate clearance 5
• Monitor vitamin B12 levels in patients on long-term metformin therapy (>4 years) 1, 4

Combination Therapy

• For most patients with T2D, CKD, and eGFR ≥30 ml/min/1.73 m², combination therapy with metformin and an SGLT2i is beneficial 2, 1
• If glycemic targets are not achieved with metformin and SGLT2i, or if these medications cannot be used, consider adding a GLP-1 receptor agonist 1, 2

Clinical Benefits vs. Risks

• Despite historical concerns, recent evidence supports the safe use of metformin in mild to moderate CKD (eGFR 30-60 ml/min/1.73 m²) with appropriate dose adjustments 8, 7
• Observational studies suggest potential benefits of metformin on cardiovascular outcomes and mortality in CKD patients 9, 7
• Some studies indicate metformin use in CKD may be associated with lower risk of progression to end-stage renal disease 9

By following these evidence-based guidelines for metformin use in CKD, clinicians can maximize the benefits of this first-line diabetes medication while minimizing risks in patients with impaired kidney function.